Blueprint Medicines Corporation (NASDAQ:BPMC - Get Free Report) insider Percy H. Carter sold 1,051 shares of the stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $128.25, for a total transaction of $134,790.75. Following the transaction, the insider owned 53,155 shares in the company, valued at approximately $6,817,128.75. The trade was a 1.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Blueprint Medicines Stock Performance
NASDAQ BPMC remained flat at $128.40 on Tuesday. 2,959,242 shares of the company's stock traded hands, compared to its average volume of 1,336,976. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 1.01. Blueprint Medicines Corporation has a twelve month low of $73.04 and a twelve month high of $129.06. The stock's fifty day moving average price is $114.35 and its 200-day moving average price is $100.83. The firm has a market cap of $8.29 billion, a price-to-earnings ratio of -51.98 and a beta of 0.89.
Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.32). Blueprint Medicines had a negative net margin of 27.70% and a negative return on equity of 64.60%. The business had revenue of $149.41 million for the quarter, compared to analyst estimates of $158.31 million. During the same quarter in the previous year, the firm posted $1.40 earnings per share. The business's revenue was up 55.5% on a year-over-year basis. On average, research analysts anticipate that Blueprint Medicines Corporation will post -1.28 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Blueprint Medicines
Several large investors have recently made changes to their positions in BPMC. Bank of New York Mellon Corp raised its position in Blueprint Medicines by 2.4% during the fourth quarter. Bank of New York Mellon Corp now owns 303,432 shares of the biotechnology company's stock worth $26,465,000 after acquiring an additional 7,101 shares during the period. Charles Schwab Investment Management Inc. raised its position in Blueprint Medicines by 1.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 604,397 shares of the biotechnology company's stock worth $52,716,000 after acquiring an additional 7,165 shares during the period. Proficio Capital Partners LLC acquired a new position in Blueprint Medicines during the fourth quarter worth $1,012,000. Arizona State Retirement System raised its position in Blueprint Medicines by 7.2% during the fourth quarter. Arizona State Retirement System now owns 18,353 shares of the biotechnology company's stock worth $1,601,000 after acquiring an additional 1,225 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in Blueprint Medicines during the fourth quarter worth $21,104,000.
Wall Street Analyst Weigh In
Several brokerages have issued reports on BPMC. Wells Fargo & Company cut shares of Blueprint Medicines from a "strong-buy" rating to a "hold" rating and dropped their target price for the stock from $143.00 to $129.00 in a report on Tuesday, June 17th. Wolfe Research cut shares of Blueprint Medicines from a "strong-buy" rating to a "hold" rating in a report on Tuesday, June 3rd. Scotiabank cut shares of Blueprint Medicines from a "strong-buy" rating to a "sector perform" rating and set a $135.00 price target on the stock. in a report on Monday, June 2nd. Cowen cut shares of Blueprint Medicines to a "hold" rating in a report on Monday, June 2nd. Finally, Wall Street Zen upgraded shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a report on Friday, May 2nd. Eighteen equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $128.06.
Read Our Latest Report on Blueprint Medicines
About Blueprint Medicines
(
Get Free Report)
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Blueprint Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Blueprint Medicines wasn't on the list.
While Blueprint Medicines currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
